Dosage ; NSAID-induced gastric ulcers: 200-800mcg QID. Dose:
Termination of 2nd trimester pregnancy; 200mcg intravaginally every 6 hours for 2 doses for a total of 4 doses.
Termination of 2nd trimester stillbirth; 200mcg intravaginally every 12 hrs. Termination of 3rd trimester stillbirth; 100mcg intravaginally every 12 hours.
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Isovent | Square Pharmaceuticals Ltd | ACE Pharmaceuticals Ltd | 200mcg | 30 | Tablet | per tablet | KES 750.00 |
| Isovent | Square Pharmaceuticals Ltd | ACE Pharmaceuticals Ltd | 200mcg | 30 | Tablet | per tablet | KES 790.00 |
| Kontrac | Fourts PVT Ltd. | Sai Pharmaceuticals Ltd. | 200mcg | 10 | Tablet | per tablet | KES 416.00 |
| Misoclear | Acme Laboratories Ltd | Unisel Pharma (K) Ltd. | 200mg | 20 | Tablet | per tablet | KES 500.00 |
| Misoclear | Acme Laboratories Ltd | Unisel Pharma (K) Ltd. | 200mg | 40 | Tablet | per tablet | KES 700.00 |
| Vagiprost | Adwia | Salama Pharmaceuticals Ltd. | 25mcg | 4 | Tablet | per tablet | KES 460.00 |
|
Misoprostol More info |
|
|---|---|
| Mode Of Action | Prostaglandin E1 analogue inhibits GI secretion, increases bicarbonate secretion and inhibits acid secretion. It induces labour by ripening the cervix and increasing uterine tone and contractility. |
| Drug Indication | NSAID-induced gastric ulcers; pro-phylaxis of NSAID-induced gastric ulcers; benign gastric and duodenal ulcers. Also used in termination of 2nd trimester pregnancy and stillbirths |
| Precautions | Predisposition to hypertension; women of child bearing age |
| Contra-Indications | Pregnancy (as it can induce abortion besides being teratogenic). Cerebrovascular or coronary artery; it worsens diarrhea; women of children unless pregnancy is ruled out. |
| Side Effects | Diarrhea; abdominal pain; flatulence; nausea and vomiting; menstrual disorders |
| Dosage | NSAID-induced gastric ulcers: 200-800mcg QID. Dose: Termination of 2nd trimester pregnancy; 200mcg intravaginally every 6 hours for 2 doses for a total of 4 doses. Termination of 2nd trimester stillbirth; 200mcg intravaginally every 12 hrs. Termination of 3rd trimester stillbirth; 100mcg intravaginally every 12 hours. |
| Special Information | It is prostaglandin E1 analogue that inhibits GI secretion, increases bicarbonate secretion and inhibits acid secretion. It is sometimes formulated as fixed-dose combinations (FDCs) with NSAIDS. The first research brand of misoprostol was Cytotec by GD Searle. It is less effective than proton pump inhibitors in reducing secretions of hydrochloric acid. |
| Pregnancy Category | Category X |
| Pregnancy Category Description | Drugs that have such a high risk of causing permanent damage to the foetus that they should be avoided in pregnancy or when there is possibility of pregnancy. |
| Drug Category | DRUGS ACTING ON GENITO-URINARY SYSTEM |
| Drug Sub-Category | Drugs acting on uterus
Dosing: Adult Prevention of NSAID-induced ulcers: Oral: 200 mcg 4 times/day with food; if not tolerated, may decrease dose to 100 mcg 4 times/day with food. Last dose of the day should be taken at bedtime. Labor induction or cervical ripening (unlabeled uses): Intravaginal: 25 mcg (1/4 of 100 mcg tablet); may repeat at intervals no more frequent than every 3-6 hours. Do not use in patients with previous cesarean delivery or prior major uterine surgery. Medical termination of pregnancy: Oral: Refer to Mifepristone monograph. Dosing: Pediatric (For additional information see "Misoprostol: Pediatric drug information") Fat absorption in cystic fibrosis (unlabeled use): Oral: Children 8-16 years: 100 mcg 4 times/day Dosing: Geriatric Oral: 100-200 mcg 4 times/day with food; if 200 mcg 4 times/day not tolerated, reduce to 100 mcg 4 times/day. Note: To avoid the diarrhea potential, doses can be initiated at 100 mcg/day and increased 100 mcg/day at 3-day intervals until desired dose is achieved; also, recommend administering with food to decrease diarrhea incidence. Dosing: Renal Impairment Half-life, maximum plasma concentration, and bioavailability may be increased; however, a correlation has not been observed with degree of dysfunction. Decrease dose if recommended dose is not tolerated. It is not known if misoprostol is removed by dialysis |